PNEUMOSTEM

Phase 1Biologic

MMedipost Co Ltd.

PNEUMOSTEM is one of 100 biologic programs targeting Bronchopulmonary Dysplasia. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Bronchopulmonary DysplasiaActive, not recruiting

HemorrhageActive, not recruiting

Pulmonary Arterial HypertensionActive, not recruiting

Bronchopulmonary DysplasiaPreclinical

Active, not recruiting

HemorrhagePhase 1

Active, not recruiting

Pulmonary Arterial HypertensionPhase 1

Active, not recruiting

Competition

Competitive Landscape

179 competitors in Pulmonary Arterial Hypertension

#DrugCompanyPhaseTrials

Gleevec

Novartis

Phase 3

6 2

Reata

Biogen

Phase 3

1 3

Levitra

Bayer

Phase 3

1 4

Aurlumyn

BBTG International Inc.

Phase 3

8 5

Flolan

Johnson & Johnson

Phase 3

1 6

Zesly

MMezzion Pharma Co. Ltd

Phase 3

1 7

Atrovent

Inhaled Iloprost

1 9

MS Contin

Merck & Co.

Phase 2

1 10

Actos

Takeda

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Active, not recruiting

Bronchopulmonary Dysplasia

NCT01632475

Q2 2027

Phase 2Active, not recruiting

Safety and Efficacy

NCT04003857

Q3 2027

Phase 1Not yet recruiting

Pulmonary Arterial Hypertension

NCT07368088

Clinical

Trials by Indication[1]

Safety and Efficacy3 trials

Follow-up Study of Safety and Efficacy in Subjects Who Completed PNEUMOSTEM® Phase II (MP-CR-012) Clinical Trial

Active, not recruiting·MMedipost Co Ltd.·Phase 2·NCT04003857·60 enrolled

Long-term Safety and Efficacy Follow-up Study of PNEUMOSTEM® in Patients Who Completed PNEUMOSTEM® Phase-I Study

Completed·MMedipost Co Ltd.··NCT02023788·8 enrolled

Follow-up Safety and Efficacy Evaluation on Subjects Who Completed PNEUMOSTEM® Phase-II Clinical Trial

Completed·MMedipost Co Ltd.·N/A·NCT01897987·62 enrolled

Efficacy and Safety2 trials

Efficacy and Safety of Pneumostem® for IVH in Premature Infants (Phase 2a)

Active, not recruiting·SSamsung Medical Center·Phase 2·NCT02890953·22 enrolled

Efficacy and Safety Evaluation of Pneumostem® Versus a Control Group for Treatment of BPD in Premature Infants

Completed·MMedipost Co Ltd.·Phase 2·NCT01828957·69 enrolled

Premature Infants1 trial

PNEUMOSTEM for the Prevention and Treatment of Severe BPD in Premature Infants

Completed·MMedipost Co Ltd.·Phase 2·NCT03392467·60 enrolled

Hemorrhage1 trial

Phase 1 Clinical Trial of PNEUMOSTEM® Treatment in Premature Infants With Intraventricular Hemorrhage

Completed·SSamsung Medical Center·Phase 1·NCT02274428·9 enrolled

Pulmonary Arterial Hypertension1 trial

PNEUMOSTEM® for Improving Respiratory Outcomes in Very Premature Infants Diagnosed With Early Pulmonary Arterial Hypertension

Not yet recruiting·SSamsung Medical Center·Phase 1·NCT07368088·12 enrolled

1 more indication

Bronchopulmonary Dysplasia1 trial

Follow-Up Study of Safety and Efficacy of Pneumostem® in Premature Infants With Bronchopulmonary Dysplasia

Active, not recruiting·SSamsung Medical Center··NCT01632475·9 enrolled

Sources

References

[1]
ClinicalTrials.gov — 9 trial records for PNEUMOSTEM. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — PNEUMOSTEM compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for PNEUMOSTEM. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Medipost Co Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: MMedipost Co Ltd.

PNEUMOSTEM

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Q2 2027

Q3 2027

Trials by Indication[1]

Safety and Efficacy3 trials

Efficacy and Safety2 trials

Premature Infants1 trial

Hemorrhage1 trial

Pulmonary Arterial Hypertension1 trial

Bronchopulmonary Dysplasia1 trial

References

Drug Info

Quick Facts

Related News